VNDA Vanda Pharma Gross Return on Sales

Corporate emblem and logo of Vanda Pharmaceuticals Inc (VNDA)

Vanda Pharmaceuticals specializes in developing medications to combat psychiatric disorders and sleep disturbances. The target gross margin confirms the resilience of these operations, with 89.30 recorded as the baseline value. Portfolio diversification mitigates patent risks, although profits rely on the sales of key drugs, necessitating strict control over litigation and generics.

VNDA - Vanda Pharmaceuticals Gross Margin over the range 07/04/2022 - 11/20/2026

Analytical breakdowns and data insights for company Vanda Pharmaceuticals Inc (VNDA)

- market value and analyst target forecast:
Fundamental valuation:Vanda Pharmaceuticals Inc. (VNDA)
Manufactured products of Vanda Pharma

For Vanda Pharmaceuticals (VNDA), which is developing Hetlioz and Fanapt for CNS therapy, the gross profit margin reflects the efficiency of managing direct production costs. This metric is calculated as the ratio of the difference between revenue and cost of goods sold to total sales, allowing investors to assess the resilience of business margins against rising production expenses and the risk of contracting operating returns.